img

Global IBS Treatment Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global IBS Treatment Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Irritable bowel syndrome (IBS) is a common disorder that affects the digestive system. IBS is characterized by symptoms such as stomach cramps, bloating, diarrhea, and constipation, which impacts one’s everyday life. Although the cause of IBS is unknown, but few factors that cause IBS are severe infection, inflammation in the intestines, muscle contractions in the intestine, changes in bacteria in the gut, and abnormalities in the nerves.
Due to the COVID-19 pandemic, the global IBS Treatment market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, IBS-D accounting for % of the IBS Treatment global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Hospitals segment is altered to an % CAGR throughout this forecast period.
Rising prevalence of gastrointestinal diseases and disorder, geriatric population, unhealthy diet, anxiety, depression, and changing lifestyle in Americas are the key drivers of the Americas IBS market. Moreover, strong clinical pipeline and government support is fuelling the market in this region. According to an updated report by the Anxiety and Depression Association of America, in 2017, the most common mental disorder was anxiety in the United States, affecting approximately 40 million adults over 18 years every year.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global IBS Treatment market. The analysts authoring the report have closely studied key strategies adopted by top players of the global IBS Treatment market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global IBS Treatment market. Readers of the report can become informed about current and future trends of the global IBS Treatment market and how they will impact market growth during the forecast period.



By Company


Allergan (Ireland)
Sucampo Pharmaceuticals (U.S.)
Ironwood Pharmaceuticals (U.S.)
Astellas Pharma (Japan)
Bausch Health
Abbott Laboratories (U.S.)
Synergy Pharmaceuticals (U.S.)
Ardelyx (U.S.)
Nestle (Switzerland)
Sebela Pharmaceuticals (Ireland)
Probi (Sweden)
Alfasigma USA (Italy)
RedHill Biopharma (Israel)
AstraZeneca (U.K)
Ipsen (France)
Novartis (Switzerland)
Takeda Pharmaceutical Company (Japan)
Synthetic Biologics (U.S.)
Protagonist Therapeutics (U.S.)
Pfizer (U.S.)
Lexicon Pharmaceuticals (U.S.)
Innovate Biopharmaceuticals (U.S.)
Segment by Type
IBS-D
IBS-C
IBS-M

Segment by Application


Hospitals
Clinics
Research Laboratories
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of IBS Treatment in global and regional level.
Chapter 3Detailed analysis of IBS Treatment companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, IBS Treatment revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global IBS Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 IBS-D
1.2.3 IBS-C
1.2.4 IBS-M
1.3 Market by Application
1.3.1 Global IBS Treatment Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Research Laboratories
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global IBS Treatment Market Size (2018-2034)
2.2 IBS Treatment Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global IBS Treatment Market Size by Region (2018-2024)
2.4 Global IBS Treatment Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 IBS Treatment Countries Ranking by Market Size
3 IBS Treatment Competitive by Company
3.1 Global IBS Treatment Revenue by Players
3.1.1 Global IBS Treatment Revenue by Players (2018-2024)
3.1.2 Global IBS Treatment Market Share by Players (2018-2024)
3.2 Global IBS Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by IBS Treatment Revenue
3.4 Global IBS Treatment Market Concentration Ratio
3.4.1 Global IBS Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by IBS Treatment Revenue in 2022
3.5 Global Key Players of IBS Treatment Head office and Area Served
3.6 Global Key Players of IBS Treatment, Product and Application
3.7 Global Key Players of IBS Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global IBS Treatment Breakdown Data by Type
4.1 Global IBS Treatment Historic Revenue by Type (2018-2024)
4.2 Global IBS Treatment Forecasted Revenue by Type (2024-2034)
5 Global IBS Treatment Breakdown Data by Application
5.1 Global IBS Treatment Historic Market Size by Application (2018-2024)
5.2 Global IBS Treatment Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America IBS Treatment Revenue by Company (2021-2024)
6.2 North America IBS Treatment Revenue by Type (2018-2034)
6.3 North America IBS Treatment Revenue by Application (2018-2034)
6.4 North America IBS Treatment Revenue by Country (2018-2034)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe IBS Treatment Revenue by Company (2021-2024)
7.2 Europe IBS Treatment Revenue by Type (2018-2034)
7.3 Europe IBS Treatment Revenue by Application (2018-2034)
7.4 Europe IBS Treatment Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific IBS Treatment Revenue by Company (2021-2024)
8.2 Asia Pacific IBS Treatment Revenue by Type (2018-2034)
8.3 Asia Pacific IBS Treatment Revenue by Application (2018-2034)
8.4 Asia Pacific IBS Treatment Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America IBS Treatment Revenue by Company (2021-2024)
9.2 Latin America IBS Treatment Revenue by Type (2018-2034)
9.3 Latin America IBS Treatment Revenue by Application (2018-2034)
9.4 Latin America IBS Treatment Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa IBS Treatment Revenue by Company (2021-2024)
10.2 Middle East and Africa IBS Treatment Revenue by Type (2018-2034)
10.3 Middle East and Africa IBS Treatment Revenue by Application (2018-2034)
10.4 Middle East and Africa IBS Treatment Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 Allergan (Ireland)
11.1.1 Allergan (Ireland) Company Details
11.1.2 Allergan (Ireland) Business Overview
11.1.3 Allergan (Ireland) IBS Treatment Products and Services
11.1.4 Allergan (Ireland) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.1.5 Allergan (Ireland) IBS Treatment SWOT Analysis
11.1.6 Allergan (Ireland) Recent Development
11.2 Sucampo Pharmaceuticals (U.S.)
11.2.1 Sucampo Pharmaceuticals (U.S.) Company Details
11.2.2 Sucampo Pharmaceuticals (U.S.) Business Overview
11.2.3 Sucampo Pharmaceuticals (U.S.) IBS Treatment Products and Services
11.2.4 Sucampo Pharmaceuticals (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.2.5 Sucampo Pharmaceuticals (U.S.) IBS Treatment SWOT Analysis
11.2.6 Sucampo Pharmaceuticals (U.S.) Recent Development
11.3 Ironwood Pharmaceuticals (U.S.)
11.3.1 Ironwood Pharmaceuticals (U.S.) Company Details
11.3.2 Ironwood Pharmaceuticals (U.S.) Business Overview
11.3.3 Ironwood Pharmaceuticals (U.S.) IBS Treatment Products and Services
11.3.4 Ironwood Pharmaceuticals (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.3.5 Ironwood Pharmaceuticals (U.S.) IBS Treatment SWOT Analysis
11.3.6 Ironwood Pharmaceuticals (U.S.) Recent Development
11.4 Astellas Pharma (Japan)
11.4.1 Astellas Pharma (Japan) Company Details
11.4.2 Astellas Pharma (Japan) Business Overview
11.4.3 Astellas Pharma (Japan) IBS Treatment Products and Services
11.4.4 Astellas Pharma (Japan) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.4.5 Astellas Pharma (Japan) IBS Treatment SWOT Analysis
11.4.6 Astellas Pharma (Japan) Recent Development
11.5 Bausch Health
11.5.1 Bausch Health Company Details
11.5.2 Bausch Health Business Overview
11.5.3 Bausch Health IBS Treatment Products and Services
11.5.4 Bausch Health IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.5.5 Bausch Health IBS Treatment SWOT Analysis
11.5.6 Bausch Health Recent Development
11.6 Abbott Laboratories (U.S.)
11.6.1 Abbott Laboratories (U.S.) Company Details
11.6.2 Abbott Laboratories (U.S.) Business Overview
11.6.3 Abbott Laboratories (U.S.) IBS Treatment Products and Services
11.6.4 Abbott Laboratories (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.6.5 Abbott Laboratories (U.S.) IBS Treatment SWOT Analysis
11.6.6 Abbott Laboratories (U.S.) Recent Development
11.7 Synergy Pharmaceuticals (U.S.)
11.7.1 Synergy Pharmaceuticals (U.S.) Company Details
11.7.2 Synergy Pharmaceuticals (U.S.) Business Overview
11.7.3 Synergy Pharmaceuticals (U.S.) IBS Treatment Products and Services
11.7.4 Synergy Pharmaceuticals (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.7.5 Synergy Pharmaceuticals (U.S.) IBS Treatment SWOT Analysis
11.7.6 Synergy Pharmaceuticals (U.S.) Recent Development
11.8 Ardelyx (U.S.)
11.8.1 Ardelyx (U.S.) Company Details
11.8.2 Ardelyx (U.S.) Business Overview
11.8.3 Ardelyx (U.S.) IBS Treatment Products and Services
11.8.4 Ardelyx (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.8.5 Ardelyx (U.S.) IBS Treatment SWOT Analysis
11.8.6 Ardelyx (U.S.) Recent Development
11.9 Nestle (Switzerland)
11.9.1 Nestle (Switzerland) Company Details
11.9.2 Nestle (Switzerland) Business Overview
11.9.3 Nestle (Switzerland) IBS Treatment Products and Services
11.9.4 Nestle (Switzerland) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.9.5 Nestle (Switzerland) IBS Treatment SWOT Analysis
11.9.6 Nestle (Switzerland) Recent Development
11.10 Sebela Pharmaceuticals (Ireland)
11.10.1 Sebela Pharmaceuticals (Ireland) Company Details
11.10.2 Sebela Pharmaceuticals (Ireland) Business Overview
11.10.3 Sebela Pharmaceuticals (Ireland) IBS Treatment Products and Services
11.10.4 Sebela Pharmaceuticals (Ireland) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.10.5 Sebela Pharmaceuticals (Ireland) IBS Treatment SWOT Analysis
11.10.6 Sebela Pharmaceuticals (Ireland) Recent Development
11.11 Probi (Sweden)
11.11.1 Probi (Sweden) Company Details
11.11.2 Probi (Sweden) Business Overview
11.11.3 Probi (Sweden) IBS Treatment Products and Services
11.11.4 Probi (Sweden) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.11.5 Probi (Sweden) Recent Development
11.12 Alfasigma USA (Italy)
11.12.1 Alfasigma USA (Italy) Company Details
11.12.2 Alfasigma USA (Italy) Business Overview
11.12.3 Alfasigma USA (Italy) IBS Treatment Products and Services
11.12.4 Alfasigma USA (Italy) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.12.5 Alfasigma USA (Italy) Recent Development
11.13 RedHill Biopharma (Israel)
11.13.1 RedHill Biopharma (Israel) Company Details
11.13.2 RedHill Biopharma (Israel) Business Overview
11.13.3 RedHill Biopharma (Israel) IBS Treatment Products and Services
11.13.4 RedHill Biopharma (Israel) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.13.5 RedHill Biopharma (Israel) Recent Development
11.14 AstraZeneca (U.K)
11.14.1 AstraZeneca (U.K) Company Details
11.14.2 AstraZeneca (U.K) Business Overview
11.14.3 AstraZeneca (U.K) IBS Treatment Products and Services
11.14.4 AstraZeneca (U.K) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.14.5 AstraZeneca (U.K) Recent Development
11.15 Ipsen (France)
11.15.1 Ipsen (France) Company Details
11.15.2 Ipsen (France) Business Overview
11.15.3 Ipsen (France) IBS Treatment Products and Services
11.15.4 Ipsen (France) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.15.5 Ipsen (France) Recent Development
11.16 Novartis (Switzerland)
11.16.1 Novartis (Switzerland) Company Details
11.16.2 Novartis (Switzerland) Business Overview
11.16.3 Novartis (Switzerland) IBS Treatment Products and Services
11.16.4 Novartis (Switzerland) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.16.5 Novartis (Switzerland) Recent Development
11.17 Takeda Pharmaceutical Company (Japan)
11.17.1 Takeda Pharmaceutical Company (Japan) Company Details
11.17.2 Takeda Pharmaceutical Company (Japan) Business Overview
11.17.3 Takeda Pharmaceutical Company (Japan) IBS Treatment Products and Services
11.17.4 Takeda Pharmaceutical Company (Japan) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.17.5 Takeda Pharmaceutical Company (Japan) Recent Development
11.18 Synthetic Biologics (U.S.)
11.18.1 Synthetic Biologics (U.S.) Company Details
11.18.2 Synthetic Biologics (U.S.) Business Overview
11.18.3 Synthetic Biologics (U.S.) IBS Treatment Products and Services
11.18.4 Synthetic Biologics (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.18.5 Synthetic Biologics (U.S.) Recent Development
11.19 Protagonist Therapeutics (U.S.)
11.19.1 Protagonist Therapeutics (U.S.) Company Details
11.19.2 Protagonist Therapeutics (U.S.) Business Overview
11.19.3 Protagonist Therapeutics (U.S.) IBS Treatment Products and Services
11.19.4 Protagonist Therapeutics (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.19.5 Protagonist Therapeutics (U.S.) Recent Development
11.20 Pfizer (U.S.)
11.20.1 Pfizer (U.S.) Company Details
11.20.2 Pfizer (U.S.) Business Overview
11.20.3 Pfizer (U.S.) IBS Treatment Products and Services
11.20.4 Pfizer (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.20.5 Pfizer (U.S.) Recent Development
11.21 Lexicon Pharmaceuticals (U.S.)
11.21.1 Lexicon Pharmaceuticals (U.S.) Company Details
11.21.2 Lexicon Pharmaceuticals (U.S.) Business Overview
11.21.3 Lexicon Pharmaceuticals (U.S.) IBS Treatment Products and Services
11.21.4 Lexicon Pharmaceuticals (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.21.5 Lexicon Pharmaceuticals (U.S.) Recent Development
11.22 Innovate Biopharmaceuticals (U.S.)
11.22.1 Innovate Biopharmaceuticals (U.S.) Company Details
11.22.2 Innovate Biopharmaceuticals (U.S.) Business Overview
11.22.3 Innovate Biopharmaceuticals (U.S.) IBS Treatment Products and Services
11.22.4 Innovate Biopharmaceuticals (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024)
11.22.5 Innovate Biopharmaceuticals (U.S.) Recent Development
12 IBS Treatment Market Dynamics
12.1 IBS Treatment Industry Trends
12.2 IBS Treatment Market Drivers
12.3 IBS Treatment Market Challenges
12.4 IBS Treatment Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global IBS Treatment Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of IBS-D
Table 3. Key Players of IBS-C
Table 4. Key Players of IBS-M
Table 5. Global IBS Treatment Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 6. Global IBS Treatment Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 7. Global IBS Treatment Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global IBS Treatment Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 9. Global IBS Treatment Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 10. Global IBS Treatment Revenue by Players (2018-2024) & (US$ Million)
Table 11. Global IBS Treatment Market Share by Players (2018-2024)
Table 12. Global Top IBS Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in IBS Treatment as of 2022)
Table 13. Ranking of Global Top IBS Treatment Companies by Revenue (US$ Million) in 2022
Table 14. Global 5 Largest Players Market Share by IBS Treatment Revenue (CR5 and HHI) & (2018-2024)
Table 15. Global Key Players of IBS Treatment, Headquarters and Area Served
Table 16. Global Key Players of IBS Treatment, Product and Application
Table 17. Global Key Players of IBS Treatment, Date of Enter into This Industry
Table 18. Mergers & Acquisitions, Expansion Plans
Table 19. Global IBS Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 20. Global IBS Treatment Revenue Market Share by Type (2018-2024)
Table 21. Global IBS Treatment Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 22. Global IBS Treatment Revenue Market Share by Type (2024-2034)
Table 23. Global IBS Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 24. Global IBS Treatment Revenue Market Share by Application (2018-2024)
Table 25. Global IBS Treatment Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 26. Global IBS Treatment Revenue Market Share by Application (2024-2034)
Table 27. North America IBS Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 28. North America IBS Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 29. North America IBS Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 30. North America IBS Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 31. North America IBS Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 32. North America IBS Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 33. North America IBS Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 34. North America IBS Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 35. Europe IBS Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 36. Europe IBS Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 37. Europe IBS Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 38. Europe IBS Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 39. Europe IBS Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 40. Europe IBS Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 41. Europe IBS Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 42. Europe IBS Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 43. Asia Pacific IBS Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 44. Asia Pacific IBS Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 45. Asia Pacific IBS Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 46. Asia Pacific IBS Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 47. Asia Pacific IBS Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 48. Asia-Pacific IBS Treatment Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 49. Asia Pacific IBS Treatment Revenue by Region (2018-2024) & (US$ Million)
Table 50. Asia Pacific IBS Treatment Revenue by Region (2024-2034) & (US$ Million)
Table 51. Latin America IBS Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 52. Latin America IBS Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 53. Latin America IBS Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 54. Latin America IBS Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 55. Latin America IBS Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 56. Latin America IBS Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 57. Latin America IBS Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 58. Latin America IBS Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 59. Middle East and Africa IBS Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 60. Middle East and Africa IBS Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 61. Middle East and Africa IBS Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 62. Middle East and Africa IBS Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 63. Middle East and Africa IBS Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 64. Middle East and Africa IBS Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 65. Middle East and Africa IBS Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 66. Middle East and Africa IBS Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 67. Allergan (Ireland) Company Details
Table 68. Allergan (Ireland) Business Overview
Table 69. Allergan (Ireland) IBS Treatment Product and Services
Table 70. Allergan (Ireland) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 71. Allergan (Ireland) IBS Treatment SWOT Analysis
Table 72. Allergan (Ireland) Recent Development
Table 73. Sucampo Pharmaceuticals (U.S.) Company Details
Table 74. Sucampo Pharmaceuticals (U.S.) Business Overview
Table 75. Sucampo Pharmaceuticals (U.S.) IBS Treatment Product and Services
Table 76. Sucampo Pharmaceuticals (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 77. Sucampo Pharmaceuticals (U.S.) IBS Treatment SWOT Analysis
Table 78. Sucampo Pharmaceuticals (U.S.) Recent Development
Table 79. Ironwood Pharmaceuticals (U.S.) Company Details
Table 80. Ironwood Pharmaceuticals (U.S.) Business Overview
Table 81. Ironwood Pharmaceuticals (U.S.) IBS Treatment Product and Services
Table 82. Ironwood Pharmaceuticals (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 83. Ironwood Pharmaceuticals (U.S.) IBS Treatment SWOT Analysis
Table 84. Ironwood Pharmaceuticals (U.S.) Recent Development
Table 85. Astellas Pharma (Japan) Company Details
Table 86. Astellas Pharma (Japan) Business Overview
Table 87. Astellas Pharma (Japan) IBS Treatment Product and Services
Table 88. Astellas Pharma (Japan) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 89. Astellas Pharma (Japan) IBS Treatment SWOT Analysis
Table 90. Astellas Pharma (Japan) Recent Development
Table 91. Bausch Health Company Details
Table 92. Bausch Health Business Overview
Table 93. Bausch Health IBS Treatment Product and Services
Table 94. Bausch Health IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 95. Bausch Health IBS Treatment SWOT Analysis
Table 96. Bausch Health Recent Development
Table 97. Abbott Laboratories (U.S.) Company Details
Table 98. Abbott Laboratories (U.S.) Business Overview
Table 99. Abbott Laboratories (U.S.) IBS Treatment Product and Services
Table 100. Abbott Laboratories (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 101. Abbott Laboratories (U.S.) IBS Treatment SWOT Analysis
Table 102. Abbott Laboratories (U.S.) Recent Development
Table 103. Synergy Pharmaceuticals (U.S.) Company Details
Table 104. Synergy Pharmaceuticals (U.S.) Business Overview
Table 105. Synergy Pharmaceuticals (U.S.) IBS Treatment Product and Services
Table 106. Synergy Pharmaceuticals (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 107. Synergy Pharmaceuticals (U.S.) IBS Treatment SWOT Analysis
Table 108. Synergy Pharmaceuticals (U.S.) Recent Development
Table 109. Ardelyx (U.S.) Company Details
Table 110. Ardelyx (U.S.) Business Overview
Table 111. Ardelyx (U.S.) IBS Treatment Product and Services
Table 112. Ardelyx (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 113. Ardelyx (U.S.) IBS Treatment SWOT Analysis
Table 114. Ardelyx (U.S.) Recent Development
Table 115. Nestle (Switzerland) Company Details
Table 116. Nestle (Switzerland) Business Overview
Table 117. Nestle (Switzerland) IBS Treatment Product and Services
Table 118. Nestle (Switzerland) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 119. Nestle (Switzerland) IBS Treatment SWOT Analysis
Table 120. Nestle (Switzerland) Recent Development
Table 121. Sebela Pharmaceuticals (Ireland) Company Details
Table 122. Sebela Pharmaceuticals (Ireland) Business Overview
Table 123. Sebela Pharmaceuticals (Ireland) IBS Treatment Product and Services
Table 124. Sebela Pharmaceuticals (Ireland) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 125. Sebela Pharmaceuticals (Ireland) IBS Treatment SWOT Analysis
Table 126. Sebela Pharmaceuticals (Ireland) Recent Development
Table 127. Probi (Sweden) Company Details
Table 128. Probi (Sweden) Business Overview
Table 129. Probi (Sweden) IBS Treatment Product and Services
Table 130. Probi (Sweden) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 131. Probi (Sweden) Recent Development
Table 132. Alfasigma USA (Italy) Company Details
Table 133. Alfasigma USA (Italy) Business Overview
Table 134. Alfasigma USA (Italy) IBS Treatment Product and Services
Table 135. Alfasigma USA (Italy) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 136. Alfasigma USA (Italy) Recent Development
Table 137. RedHill Biopharma (Israel) Company Details
Table 138. RedHill Biopharma (Israel) Business Overview
Table 139. RedHill Biopharma (Israel) IBS Treatment Product and Services
Table 140. RedHill Biopharma (Israel) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 141. RedHill Biopharma (Israel) Recent Development
Table 142. AstraZeneca (U.K) Company Details
Table 143. AstraZeneca (U.K) Business Overview
Table 144. AstraZeneca (U.K) IBS Treatment Product and Services
Table 145. AstraZeneca (U.K) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 146. AstraZeneca (U.K) Recent Development
Table 147. Ipsen (France) Company Details
Table 148. Ipsen (France) Business Overview
Table 149. Ipsen (France) IBS Treatment Product and Services
Table 150. Ipsen (France) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 151. Ipsen (France) Recent Development
Table 152. Novartis (Switzerland) Company Details
Table 153. Novartis (Switzerland) Business Overview
Table 154. Novartis (Switzerland) IBS Treatment Product and Services
Table 155. Novartis (Switzerland) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 156. Novartis (Switzerland) Recent Development
Table 157. Takeda Pharmaceutical Company (Japan) Company Details
Table 158. Takeda Pharmaceutical Company (Japan) Business Overview
Table 159. Takeda Pharmaceutical Company (Japan) IBS Treatment Product and Services
Table 160. Takeda Pharmaceutical Company (Japan) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 161. Takeda Pharmaceutical Company (Japan) Recent Development
Table 162. Synthetic Biologics (U.S.) Company Details
Table 163. Synthetic Biologics (U.S.) Business Overview
Table 164. Synthetic Biologics (U.S.) IBS Treatment Product and Services
Table 165. Synthetic Biologics (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 166. Synthetic Biologics (U.S.) Recent Development
Table 167. Protagonist Therapeutics (U.S.) Company Details
Table 168. Protagonist Therapeutics (U.S.) Business Overview
Table 169. Protagonist Therapeutics (U.S.) IBS Treatment Product and Services
Table 170. Protagonist Therapeutics (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 171. Protagonist Therapeutics (U.S.) Recent Development
Table 172. Pfizer (U.S.) Company Details
Table 173. Pfizer (U.S.) Business Overview
Table 174. Pfizer (U.S.) IBS Treatment Product and Services
Table 175. Pfizer (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 176. Pfizer (U.S.) Recent Development
Table 177. Lexicon Pharmaceuticals (U.S.) Company Details
Table 178. Lexicon Pharmaceuticals (U.S.) Business Overview
Table 179. Lexicon Pharmaceuticals (U.S.) IBS Treatment Product and Services
Table 180. Lexicon Pharmaceuticals (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 181. Lexicon Pharmaceuticals (U.S.) Recent Development
Table 182. Innovate Biopharmaceuticals (U.S.) Company Details
Table 183. Innovate Biopharmaceuticals (U.S.) Business Overview
Table 184. Innovate Biopharmaceuticals (U.S.) IBS Treatment Product and Services
Table 185. Innovate Biopharmaceuticals (U.S.) IBS Treatment Revenue in IBS Treatment Business (2018-2024) & (US$ Million)
Table 186. Innovate Biopharmaceuticals (U.S.) Recent Development
Table 187. IBS Treatment Market Trends
Table 188. IBS Treatment Market Drivers
Table 189. IBS Treatment Market Challenges
Table 190. IBS Treatment Market Restraints
Table 191. Research Programs/Design for This Report
Table 192. Key Data Information from Secondary Sources
Table 193. Key Data Information from Primary Sources
List of Figures
Figure 1. IBS Treatment Product Picture
Figure 2. Global IBS Treatment Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global IBS Treatment Market Share by Type: 2022 VS 2034
Figure 4. IBS-D Features
Figure 5. IBS-C Features
Figure 6. IBS-M Features
Figure 7. Global IBS Treatment Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 8. Global IBS Treatment Market Share by Application: 2022 VS 2034
Figure 9. Hospitals
Figure 10. Clinics
Figure 11. Research Laboratories
Figure 12. IBS Treatment Report Years Considered
Figure 13. Global IBS Treatment Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 14. Global IBS Treatment Market Size 2018-2034 (US$ Million)
Figure 15. Global IBS Treatment Market Size Market Share by Region: 2022 VS 2034
Figure 16. Global IBS Treatment Revenue Market Share by Region in 2018 VS 2022
Figure 17. Global IBS Treatment Revenue Market Share Forecast by Region (2024-2034)
Figure 18. Global Top 10 IBS Treatment Countries Ranking by Market Size (US$ Million) in 2022
Figure 19. Global IBS Treatment Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 20. Global IBS Treatment Market Share by Players in 2022
Figure 21. Global Top IBS Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in IBS Treatment as of 2022)
Figure 22. The Top 10 and 5 Players Market Share by IBS Treatment Revenue in 2022
Figure 23. North America IBS Treatment Revenue Market Share by Company in 2022
Figure 24. North America IBS Treatment Revenue Market Share by Type (2018-2034)
Figure 25. North America IBS Treatment Revenue Market Share by Application (2018-2034)
Figure 26. North America IBS Treatment Revenue Share by Country (2018-2034)
Figure 27. U.S. IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 28. Canada IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 29. Europe IBS Treatment Revenue Market Share by Company in 2022
Figure 30. Europe IBS Treatment Revenue Market Share by Type (2018-2034)
Figure 31. Europe IBS Treatment Revenue Market Share by Application (2018-2034)
Figure 32. Europe IBS Treatment Revenue Share by Country (2018-2034)
Figure 33. Germany IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 34. France IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 35. U.K. IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 36. Italy IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 37. Russia IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 38. Asia Pacific IBS Treatment Revenue Market Share by Company in 2022
Figure 39. Asia Pacific IBS Treatment Revenue Market Share by Type (2018-2034)
Figure 40. Asia Pacific IBS Treatment Revenue Market Share by Application (2018-2034)
Figure 41. Asia Pacific IBS Treatment Revenue Share by Region (2018-2034)
Figure 42. China IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 43. Japan IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 44. South Korea IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 45. India IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 46. Australia IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 47. Taiwan IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 48. Indonesia IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 49. Thailand IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 50. Malaysia IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 51. Philippines IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 52. Vietnam IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 53. Latin America IBS Treatment Revenue Market Share by Company in 2022
Figure 54. Latin America IBS Treatment Revenue Market Share by Type (2018-2034)
Figure 55. Latin America IBS Treatment Revenue Market Share by Application (2018-2034)
Figure 56. Latin America IBS Treatment Revenue Share by Country (2018-2034)
Figure 57. Mexico IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 58. Brazil IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 59. Argentina IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 60. Middle East and Africa IBS Treatment Revenue Market Share by Company in 2022
Figure 61. Middle East and Africa IBS Treatment Revenue Market Share by Type (2018-2034)
Figure 62. Middle East and Africa IBS Treatment Revenue Market Share by Application (2018-2034)
Figure 63. Middle East and Africa IBS Treatment Revenue Share by Country (2018-2034)
Figure 64. Turkey IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 65. Saudi Arabia IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 66. U.A.E IBS Treatment Revenue (2018-2034) & (US$ Million)
Figure 67. Allergan (Ireland) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 68. Sucampo Pharmaceuticals (U.S.) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 69. Ironwood Pharmaceuticals (U.S.) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 70. Astellas Pharma (Japan) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 71. Bausch Health Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 72. Abbott Laboratories (U.S.) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 73. Synergy Pharmaceuticals (U.S.) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 74. Ardelyx (U.S.) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 75. Nestle (Switzerland) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 76. Sebela Pharmaceuticals (Ireland) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 77. Probi (Sweden) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 78. Alfasigma USA (Italy) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 79. RedHill Biopharma (Israel) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 80. AstraZeneca (U.K) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 81. Ipsen (France) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 82. Novartis (Switzerland) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 83. Takeda Pharmaceutical Company (Japan) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 84. Synthetic Biologics (U.S.) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 85. Protagonist Therapeutics (U.S.) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 86. Pfizer (U.S.) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 87. Lexicon Pharmaceuticals (U.S.) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 88. Innovate Biopharmaceuticals (U.S.) Revenue Growth Rate in IBS Treatment Business (2018-2024)
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed